HCAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Health Catalyst Inc (HCAT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, insider selling, and declining revenue. While there are slight improvements in net income, EPS, and gross margin, these are not sufficient to outweigh the negative trends. Analysts have lowered the price target, and there are no significant positive catalysts or recent news to support a buy decision. Holding off on this stock is recommended until stronger positive signals emerge.
The technical indicators are bearish. The MACD histogram is below 0 and negatively contracting, the RSI is neutral at 37.212, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 1.818, with key support at 1.69 and resistance at 1.946.
Slight improvements in net income (+50.95% YoY), EPS (+33.33% YoY), and gross margin (+8.25% YoY) in Q3 2025.
Revenue decline (-0.04% YoY), bearish technical indicators, insider selling increased by 869.22% in the last month, and analysts lowering the price target. No recent news or significant trading trends.
In Q3 2025, revenue dropped slightly to $76.32M (-0.04% YoY). Net income improved to -$22.23M (+50.95% YoY), EPS increased to -0.32 (+33.33% YoY), and gross margin rose to 34.51% (+8.25% YoY).
Citi recently lowered the price target from $3.25 to $2.75 and maintained a Neutral rating. Analysts are cautiously optimistic for 2026 but acknowledge challenges in the health tech sector in 2025.
